資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://libir.tmu.edu.tw/handle/987654321/64240
|
| 題名: | 合成1H吡咯[2,3-b]吡啶衍生物作為激酶抑制劑
Synthesis of 1H-Pyrrolo[2,3-b]pyridine Derivatives as Kinase Inhibitors |
| 作者: | 黃奕霖
HWANG, YI-LIN |
| 貢獻者: | 藥學系碩士班
李學耘 |
| 關鍵詞: | 激酶抑制劑;1H吡咯[2,3-b]吡啶
Kinase inhibitor;1H-Pyrrolo[2,3-b]pyridine |
| 日期: | 2024-06-18 |
| 上傳時間: | 2024-09-11 19:13:59 (UTC+8) |
| 摘要: | 癌症是至今為止最致命的疾病之一，每年有超過1000萬人死於癌症。因此，攻剋癌症已是刻不容緩的任務。 隨著過去幾十年化學和生物學的進步，癌症治療的選擇越來越多，而針對蛋白激?是最有前景的方法之一。蛋白激?在人體的生物學功能中發揮重要作用，包括腫瘤細胞的發育。據文獻指出，絲裂原活化蛋白激? (MAP4K4) 與癌症息息相關，例如神經母細胞瘤、大腸直腸癌、前列腺癌和胰腺癌。即便研究清楚指出癌症與MAP4K4的過度表現有關，現行的MAP4K4抑制劑的數量並不多，因而啟發我們進行新穎MAP4K4的設計與合成。 本研究利用基於小片段結構虛擬篩選(Fragment-based virtual screening)，發現了一系列具有 3-(1,2,3,6-四氫?啶-4-基)-7-氮雜??共同結構的 MAP4K4 抑制劑。我們進行了結構活性關係的研究(SAR)，總共合成了 16 個化合物並完成了體外激?活性的測定。化合物 10 的激? IC50值為 15.8 nM，被發現是所合成化合物中最有效的。這項研究的結果確立了新穎的結構片段作為MAP4K4的抑制劑，帶來良好的結果，並且需要進一步的生物學評估來確定它們作為抗癌製劑。
Cancer is one of the deadliest diseases to date, more than 10 million people die of cancer each year. Therefore, tackling cancer is an imperative task. As advances in chemistry and biology have been made in the past few decades, there have been an increasing amount of treatment options, and targeting protein kinases is one of the promising methods. Protein kinases play a significant role in the biological functions of the human body, including the development of tumor cells. Mitogen-activated protein kinase kinase kinase kinase (MAP4K4) is reported to correlate with a handful of cancers, such as glioblastoma, colorectal cancer, prostate cancer, and pancreatic cancer. Despite the clear correlations between cancer and MAP4K4 overexpression, there is a lack of known inhibitors to date, which intrigued us to develop novel MAP4K4 inhibitors. This study utilizes fragment-based-virtual screening and discovered a series of MAP4K4 inhibitors possessing common structures of 3-(1,2,3,6-tetrahydropyridin-4-yl)-7-azaindoles. A structure-activity relationship (SAR) study was performed, a total of 16 compounds were synthesized and in-vitro kinase assays were completed. Compound 10 possesses a kinase IC50 value of 15.8 nM and was found to be the most potent compound of all. This study established a novel scaffold of MAP4K4 inhibitors, as well as delivered promising results. and will require further biological evaluations to establish them as anti-cancer agents. |
| 描述: | 碩士
指導教授：李學耘
口試委員：李學耘
口試委員：許凱程
口試委員：皇甫維君 |
| 資料類型: | thesis |
| 顯示於類別: | [藥學系] 博碩士論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 61 | 檢視/開啟 |
|
在TMUIR中所有的資料項目都受到原著作權保護.
|
